Fresenius Medical Care (NYSE: FMS) reported Q4 EPS of EUR0.88, EUR0.45 better than the analyst estimate of EUR0.43. Revenue for the quarter came in at EUR4.99 billion versus the consensus estimate of EUR5.36 billion.

OUTLOOK

In 2024, Fresenius Medical Care expects revenue to grow by a low- to mid-single digit percent rate compared to prior year.

The Company expects operating income to grow by a mid- to high-teens percent rate compared to prior year.

The expected growth rates for 2024 are at constant currency, excluding special items. The 2023 basis for the revenue outlook is EUR 19,049 million and for the operating income outlook is EUR 1,540 million, both numbers are adjusted for the positive impact of the Tricare settlement and the operating business impact from divestments closed by year-end 2023.

The Company reconfirms its targets to achieve an operating income margin of 10% to 14% by 2025. This excludes impacts from portfolio changes.

For earnings history and earnings-related data on Fresenius Medical Care (FMS) click here.